Durvalumab Plus Chemo Improves Survival for Small Cell Lung Cancer - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer 10/31/2019 A large clinical trial showed that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy can prolong survival in some people with previously untreated advanced small cell lung cancer.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892